CorMedix Inc
CRMD16.560USD
+2.950+21.68%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
1.12BMarket Cap
LossP/E TTM
More Details of CorMedix Inc Company
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Company Info
Ticker SymbolCRMD
Company nameCorMedix Inc
IPO dateMar 25, 2010
Founded at2006
CEOMr. Joseph Todisco
Number of employees64
Security typeOrdinary Share
Fiscal year-endMar 25
Address300 Connell Drive
CityBERKELEY HEIGHTS
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code07922
Phone19085179500
Websitehttps://cormedix.com/
Ticker SymbolCRMD
IPO dateMar 25, 2010
Founded at2006
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Executive Vice President, Chief Clinical Strategy and Operations Officer
Executive Vice President, Chief Clinical Strategy and Operations Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Beth Zelnick Kaufman
Ms. Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Revenue Breakdown
FY2024
No Data
By RegionUSD
Name
Revenue
Proportion
United States
43.47M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
Shareholder Types
Shareholders
Proportion
Investment Advisor
13.86%
Investment Advisor/Hedge Fund
13.60%
Hedge Fund
5.69%
Research Firm
1.60%
Sovereign Wealth Fund
1.39%
Individual Investor
1.19%
Pension Fund
0.45%
Bank and Trust
0.30%
Venture Capital
0.06%
Other
61.88%
Institutional Shareholding
Updated: Mon, Feb 24
Updated: Mon, Feb 24
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
262
29.51M
43.73%
+3.54M
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
2023Q1
190
11.28M
25.34%
-2.76M
2022Q4
191
11.93M
28.90%
-1.83M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.20M
6.44%
+868.26K
+26.06%
Dec 31, 2024
The Vanguard Group, Inc.
3.38M
5.18%
+309.51K
+10.09%
Dec 31, 2024
Elliott Management Corporation
2.87M
4.4%
+1.32M
+85.14%
Dec 31, 2024
State Street Global Advisors (US)
1.45M
2.23%
+227.39K
+18.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.39M
2.14%
+108.36K
+8.44%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
940.59K
1.44%
+940.59K
--
Dec 31, 2024
UBS Financial Services, Inc.
379.87K
0.58%
+340.35K
+861.30%
Dec 31, 2024
Morgan Stanley & Co. LLC
283.12K
0.43%
+50.06K
+21.48%
Dec 31, 2024
Northern Trust Investments, Inc.
510.89K
0.78%
+100.11K
+24.37%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
SPDR S&P Pharmaceuticals ETF
1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
First Trust Active Factor Small Cap ETF
0.17%
iShares Micro-Cap ETF
0.13%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
View more
SPDR S&P Pharmaceuticals ETF
Proportion1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.49%
First Trust Active Factor Small Cap ETF
Proportion0.17%
iShares Micro-Cap ETF
Proportion0.13%
Vanguard US Momentum Factor ETF
Proportion0.1%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
iShares Biotechnology ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
